Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer.

Clinical colorectal cancer·2026
Same author

Community Safety Needs and Resources and Their Alignment: A Case Study.

Journal of urban health : bulletin of the New York Academy of Medicine·2026
Same author

Podium Abstracts Presented at the 2025 Annual Meeting of the Arthroscopy Association of North America.

Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association·2026
Same author

Renal tumors harboring FLCN mutations: Case series from clinical practice.

Human pathology·2026
Same author

Survey Study of Canadian Orthopedic Surgeons on the Surgical Management of Anterior Cruciate Ligament Injury.

Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine·2026
Same author

Digitally Assessed Nucleolar Size Compared to Traditional Pathologist WHO Grade Allocation in Clear Cell Renal Cell Carcinoma.

International journal of surgical pathology·2026
Same journal

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

Related Experiment Video

Updated: Apr 14, 2026

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
05:22

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

195

Biliary tract cancers: understudied and poorly understood.

Emily Chan1, Jordan Berlin2

  • 1All authors: Vanderbilt University, Nashville, TN. Emily.chan@vanderbilt.edu.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|April 29, 2015
PubMed
Summary
This summary is machine-generated.

Biliary tract cancers (BTC) are diverse. While surgery and radiation treat localized BTC, effective adjuvant therapies are lacking, and gemcitabine plus cisplatin is standard for metastatic disease.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K
Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

950

Related Experiment Videos

Last Updated: Apr 14, 2026

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
05:22

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

195
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K
Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

950

Area of Science:

  • Oncology
  • Gastroenterology
  • Cancer Research

Background:

  • Biliary tract cancers (BTC) encompass intrahepatic, extrahepatic bile duct, and gallbladder cancers.
  • Localized BTC is treated with surgery and radiation, but effective adjuvant therapies remain elusive.
  • Gemcitabine plus cisplatin is the standard chemotherapy for metastatic BTC, based on limited trial data.

Purpose of the Study:

  • To review the current landscape of biliary tract cancer treatment.
  • To highlight the challenges and future directions in managing these heterogeneous malignancies.
  • To emphasize the need for targeted therapies and careful patient selection.

Main Methods:

  • Review of existing clinical trial data and treatment guidelines for BTC.
  • Analysis of the role of chemotherapy and emerging targeted therapies.
  • Discussion of the impact of genetic mutations on treatment strategies.

Main Results:

  • No definitive effective adjuvant therapy is established for BTC.
  • Gemcitabine plus cisplatin is the current standard for metastatic disease.
  • Genetic mutations offer potential for targeted therapies, but early trials in unselected patients yielded negative results.

Conclusions:

  • Targeted therapy development for BTC requires careful patient selection based on specific genetic mutations.
  • Future research must focus on identifying activated targets in smaller patient subsets to improve outcomes.
  • Despite challenges, identifying actionable mutations is crucial for advancing BTC treatment.